Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

NCT04433845 is registered in ClinicalTrials.gov with Sheppard Pratt Health System as lead sponsor.

NCT NCT04433845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04433845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Lead sponsor
Sheppard Pratt Health System
Phase
Phase 2
Overall status
Unknown status
Start date
March 1, 2021
Completion date
April 15, 2023
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression